Hits: 845
TUCSON, AZ, USA I December 8, 2020 I Procyon Technologies LLC today announced that it has entered into an exclusive research collaboration and license agreement with Novo Nordisk A/S to develop an implantable cell encapsulation device to be used in Novo Nordisk s development of a novel therapy for Type 1 diabetes.
The collaboration brings together Procyon Technologies expertise with development of oxygen enabled implantable cell encapsulation devices and Novo Nordisk s expertise in stem cell-derived insulin-secreting cells.
The partners will work together to further optimize the device and cells for clinical testing and accelerate the path to First Human Dose with the joint vision of delivering a functional cure for people living with Type 1 diabetes.